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Abstract
Maintenance  of  genomic  stability  is  crucial  in  ensuring  cellular  homeostasis  and
perpetuation  of  life.  Perpetuation  of  the  genetic  information  relies  upon  faithful
replication of the genome. Mutations, generated during DNA synthesis and/or cell
division and induced by exposure to external chemical agents, are drivers of genetic
and associated genomic instability believed to fuel malignant transformation. Curious‐
ly,  pluripotent  stem  cells  (PSCs)  are  characterized  by  a  high  degree  of  genomic
instability of  unknown origin,  which resembles that  observed in cancer cells.  This
peculiar feature of PSCs raises the questions of the reasons responsible for this apparent
aberrant  regulation  and of  how genome integrity  is  kept  under  control.  Genomic
instability  of  PSCs  also  raises  important  concerns  about  their  use  in  regenerative
medicine, which sets severe limitations in clinical applications. The aim of this chapter
is to review current knowledge about the molecular grounds of genomic instability of
PSCs of diverse origin, such as embryonic (ESCs), induced pluripotent (iPSCs), and
adult (ASCs) stem cells. We will also review how these features undermine the use of
PSCs in clinical applications and discuss new emerging perspectives aimed at reducing
genomic instability so to improve their use in clinical applications.
Keywords: DNA damage, checkpoints, replication stress, oncogenesis, nucleus, chro‐
matin
1. Introduction
Maintenance of genome stability is primordial for stem cells, given their potential to generate
multiple distinct cell lineages. Mutations may lead to the inheritance of DNA discontinuities in
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
differentiated cells with potentially catastrophic consequences such as chromosomal rearrange‐
ments and deletions [1]. Genetic aberrancies can affect the stem cell pool or increase the chances
of  malignant  transformation  since  these  can  lead  to  oncogenes  activation  and/or  tumor
suppressors silencing [2, 3]. Paradoxically, embryonic stem cells (ESCs) and induced pluripo‐
tent stem cells (iPSCs) display signs of genomic instability, to a level comparable to that observed
in cancer cells [4]. In contrast, adult stem cells (ASCs), which have a strongly reduced pluripo‐
tency,  appear  to  have  more  stable  genomes.  The  occurrence  of  genomic  instability  also
undermines the use of PSCs in regenerative medicine since these cells are known to induce
tumors once injected in the organism.
2. Molecular basis of genomic instability
Genomic instability consists in the tendency of cells to accumulate mutations that directly or
indirectly affect the structure of the genome, such as deletions, translocations, variation in the
chromosomes copy number (CNVs) [5]. Maintenance of genome stability depends upon
cellular processes that regulate DNA metabolism, such as DNA replication, transcription,
repair, chromatin remodeling and their coordination with the cell cycle. Such coordination is
orchestrated by cell cycle checkpoints [6]. Once activated, these signaling pathways slow down
the cell cycle, activate DNA repair, and promote recovery of proliferation so to ensure that
genetic information is faithfully transmitted to the daughter cells. For instance, the S-phase
checkpoint restrains the onset of M-phase so to ensure that all DNA has been replicated before
cells enter division. On the other hand, M-phase checkpoint delays anaphase so to ensure that
condensed chromosomes are faithfully transmitted to the daughter cell. Importantly, check‐
points also preserve tissues homeostasis, since they can trigger cell death to avoid propagation
of cells with unstable and/or highly damaged genomes [5, 7] (see also Figure 1).
Figure 1. Main causes of genomic instability. Schematic representation of the main causes of genomic instability ob‐
served in cells. See text for more details.
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2.1. DNA damage
Exogenous cues, such as chemical and radiations, for instance, but equally the metabolism of
the DNA itself, generate DNA damage that threatens genome integrity. DNA damage elicits
a DNA damage response (DDR) by activating cell cycle checkpoints [8]. Efficient DNA repair
mechanisms ensure that DNA lesions are fixed to minimize loss or modification of the genetic
information; among these are nucleotide excision repair (NER), base excision repair (BER),
mismatch repair (MMR), post-replication repair (PRR), interstrand crosslinks (ICL) repair,
homologous recombination (HR), and non-homologous end joining (NHEJ). A defect in any
of these DNA repair pathways can compromise genome stability directly, by affecting the
structure of the chromosome, or indirectly by generating mutations in genes important for the
maintenance of genomic stability. Hence, occurrence of mutations in genes controlling cell
cycle checkpoints, promote strong chromosome imbalance [9]. Notwithstanding, not all of
these pathways allow faithfully repair of DNA lesions. For instance, repair of double-strand
breaks (DSBs) by NHEJ, which involves fusion of broken DNA ends after processing without
template assistance, is error-prone [10], in contrast to HR which requires a DNA template for
repair and is more error-free. Equally, ICL repair and PRR, both involving DNA translesion
synthesis, are also error-prone.
2.2. DDR
The DDR involves the activation of apical PI3KK protein kinases DNA–PKcs, ATR, and ATM.
ATR is most closely related to ATM, a protein kinase encoded by the gene mutated in the ataxia
telangiectasia syndrome. This disorder is characterized by a greatly reduced ability to repair
radiation-induced DSBs and increased risk of developing cancer [11]. Activation of PI3KK
follows a phosphorylation cascade that leads to the activation of a large number of substrates
[12], among which the tumor suppressor proteins p53, BRCA1, and CHK1. These proteins also
gather at sites of DNA damage and inhibit DNA replication and cell division apart from
promoting DNA repair, recombination, or apoptosis. For example, activated CHK1 (its
phosphorylated form) delays cell cycle progression, stabilizes stalled replication forks, and
induces the S-phase checkpoint [13]. ATR is activated following several forms of DNA damage,
including damaged nucleotides, stalled replication forks, and indirectly by DSBs [14]. ATM
instead is more specialized in the response to DSBs and in sensing modifications of the
chromatin state. DNA–PKcs is involved in the repair of DSBs by non-homologous recombi‐
nation, and more recently, it has also been implicated in signaling DNA damage synergistically
with ATR [15–17]. CHK1 and/or CHK2 phosphorylation mediates cell cycle slow down or
arrest by affecting the stability and post-translational state of master cell cycle regulators, such
as CDC25 proteins (A, B, and C) and CDKs.
In S-phase, ATR is chromatin-bound to monitor replication fork progression [18] and is
activated following generation of excess single-stranded (ss) DNA as a result of replication
forks delay or stalling at damaged sites [19]. ATR activation requires synthesis of replication
intermediates onto ssDNA followed by the recruitment of specific proteins that recognize this
substrate, such as Rad17 and the 9-1-1 checkpoint clamp [20–24]. ATR-dependent phosphor‐
ylation of the histone variant H2AX (γH2AX) constitutes a widely used marker of replication
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stress (RS) and genomic instability [25]. ATR can be also recruited and activated at DSBs
following generation of ssDNA by resection [14].
ATM assembles at DSBs immediately after their formation. Its recruitment depends upon the
MRN trimeric complex (made of Mre11, Rad50, and Nbs1 proteins), which holds two DNA
ends together, by interacting with Nbs1. DNA damage results in ATM conversion from an
inactive homodimer into an active monomer with protein kinase activity [26], which phos‐
phorylates effector molecules that carry out the DDR including H2AX, p53, BRCA1, CHK2,
RAD17, RAD9, NBS1 to form repair foci. The MDC1 protein is recruited by γH2AX via its BRCT
domains and is phosphorylated by ATM, mediating the localization of ubiquitin ligase RNF8
that triggers monoubiquitination of H2AX. RNF168, a second ubiquitin ligase, is recruited and
amplifies the ubiquitination response resulting in γH2AX polyubiquitination, which leads to
the recruitment of Rad18, p53-binding protein 1 (53BP1), and BRCA1, among other proteins
thus promoting DBSs repair by either HR or NHEJ [27].
2.3. RS
RS, defined as a more or less pronounced slow down or arrest of the DNA replication process,
is a major source of genomic instability in proliferating cells [28]. Many obstacles can interfere
with DNA synthesis. These can be specialized DNA or chromatin structures, or DNA damage
(see below). The metabolism of the cell can also induce RS by affecting the availability of
nucleotides and/or proteins required for DNA synthesis [29], as well as by production of
reactive oxygen species (ROS) that generate a large amount of DNA lesions (about 100,000 per
cell per day in an organism) [30]. RS is also generated by interference between DNA synthesis
and DNA transcription induced, for instance, by unscheduled re-entry into the cell cycle, a
situation observed during malignant transformation [31] and during reprogramming of
somatic cells into iPSCs (see Section 3.2). Conflicts between DNA replication and transcription
may lead to under replication of the genome [32, 33] as a result of DNA synthesis arrest, or to
over replication as a result of aberrant reinitiation of DNA synthesis induced by certain
oncogenes [32]. RS induces DNA damage (whose molecular bases are not completely under‐
stood) and thus generates a cellular response similar to that observed when cells are challenged
with DNA damaging agents.
At the molecular level, the consequence of RS can be: (a) generation of excess ssDNA if the
progression of the DNA polymerases and not that of the replicative DNA helicase is perturbed.
In this situation, the ssDNA binding protein RPA is recruited and the replication fork can
undergo remodeling in a process known as fork regression, dependent upon the Rad51 protein,
to limit the extent of ssDNA; (b) a pause or a permanent arrest of the replication fork with no
excess ssDNA formation due to an impediment to both DNA polymerases and helicase
activities ([34] for review). In this situation, stalled replication forks can restart through
generation of DSBs followed by resection and HR mediated by the PARP-1 enzyme [28]. (c)
Generation of extra copies of the DNA as a result of over replication of the genome leading to
collision between replication forks [32]. Recent evidence highlights the presence of regressed
replication forks in G2/M phases generated by unscheduled activation of Cyclin E and CDC25A
[35]. At this stage, the endonuclease Mus81 can cleave the DNA and replication can occur to
Pluripotent Stem Cells - From the Bench to the Clinic122
minimize the lost of genetic information. Nevertheless, DNA damage that could not be fixed
before entering mitosis persists in the next cell cycle leading to the formation of nuclear bodies
containing 53BP1 in G1 phase [36]. These nuclear bodies appear symmetrical in the two
daughter cells suggesting that they probably mark sister loci from the previous S-phase, where
unresolved replication intermediates are still present. This ATM-dependent process hints to
the possibility that ATM activation by RS is necessary to preserve genome integrity into
following cell cycles.
RS-induced genome instability is a feature of almost all human cancers which can arise from
mutations in DNA repair genes as stated by the mutator hypothesis [37]. According to this
model, genomic instability is present in precancerous lesions and causes tumor development
by increasing the spontaneous mutation rate. Then, mutations occurring in genes controlling
the DNA damage checkpoint would allow anarchic proliferation of cells having collapsed
replication forks and unstable genomes [38, 39]. The main instability found in cancer cells is
chromosomal instability (CIN) or CNVs, where chromosome structure and number varies
significantly in comparison with normal cells. Cancer cells can show other forms of genomic
instability, including microsatellite instability (MSI or MIN), in which the number of DNA
repeats present in microsatellite sequences increases or decreases [40, 41] in addition to
increased frequencies of base pair mutations [42, 43].
3. Genomic instability of stem cells
Genomic instability has been extensively reported for ESCs, while ASCs appear to have a much
more stable genome. Chromosomes 8 and 11 trisomy in ESCs [44, 45] and trisomy of chromo‐
somes 12 and 17 in hESCs [46] with the amplification of the chromosome arm 20p in these
latter have been observed [47]. These changes were reported to confer proliferation advantage.
In addition, hESCs were reported to have the tendency to become aneuploid [48]. Very recent
data now suggest that aneuploidy in hESCs arises as consequence of RS and chromosome
condensation defects [49]. Detection of several markers of RS has been reported in ESCs
(though without full activating the DDR) compared with somatic cells, suggesting that ESCs
have a strong predisposition to genetic instability. One explanation for this feature may be that
ESCs exhibit a contracted cell cycle structure, consisting of a short G1- and G2-phase and a high
proportion of cells in S-phase [50–53]. These cells are also marked by open heterochromatic
structure and an abundance of chromatin-remodeling factors [54, 55].
3.1. ESCs
Due to a highly contracted cell cycle, mESCs have an inefficient G1/S checkpoint which does
not allow them to arrest in G1 in the presence of DNA damage [56–58], while the S-phase
checkpoint is normally activated [53]. The consequence of this regulation is that lesions
generated in G1 are not sensed and therefore cannot be efficiently repaired, so they will persist
in S-phase. For instance, unrepaired ssDNA breaks generated in G1 may be replicated during
S-phase, thus generating DSBs that in turn can induce genomic rearrangements. Curiously,
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the situation seems to be inversed in hESCs, where the G1/S checkpoint has been suggested to
be functional [59], while the S-phase checkpoint appears to be inefficient [60]. This difference
can be explained as possible differences in the molecular circuits that regulate pluripotency
between mouse and human stem cells. Absence of a G1/S checkpoint in mESCs was originally
suggested to be due to inefficient p53 function [57]. However, it has been shown that p53 can
transactivate target genes in these cells [53, 56, 61]. The molecular grounds of inefficient G1/S
checkpoint in mESCs have been more recently explained by the presence of high levels of the
CDC25A phosphatase [58] due to its stabilization by the ubiquitin hydrolase DUB3 which is
expressed at high levels in mESCs [53]. This results in constitutive dephosphorylation of the
CDK2 kinase, which pushes cells into S-phase even in the presence of DNA damage, similar
to the phenotype observed in cancer cells overexpressing CDC25A [62]. Interestingly, DUB3
has been shown to regulate the ubiquitination of both H2AX and γH2AX in somatic cells [63].
If this is also the case in mESCs, then it may explain why these cells repair inefficiently DSBs
[64], aside from expressing low levels of DNA–PKcs [65]. Suppression of the G1/S checkpoint
is untimely linked to pluripotency. The expression of the DUB3 gene in mESCs [53] and that
of the CDC25A gene in hESCs [66] are under control of pluripotency factors. Indeed, down‐
regulation of CDC25A induces a G1/S delay upon DNA damage and cells spontaneously
differentiate [53]. Consistent with this observation, DUB3 is more rapidly downregulated than
OCT4 upon onset of differentiation (starting from day 1), making this gene a novel and highly
specific marker of pluripotency in mESCs. Another work has shown that the contraction of the
G1 phase is crucial to suppress differentiation of mESCs [67]. Collectively these observations
suggest that cell cycle contraction is an essential feature of pluripotency in mESCs.
mESCs exhibit spontaneous formation of γH2AX, RPA, and Rad51 foci but do not appear to
display DSBs accumulation consistent with the absence of 53BP1 foci [68, 69], although
activation of downstream DDR transducers (CHK1/2, CDC25A) does not seem to be affected
[53]. It is possible to envisage the presence of multiple levels of regulation of the S-phase
checkpoint by various factors, such as effectors of signaling pathways, unique to stem cells.
One example is provided by the observation that the CHK2 kinase appears to be sequestered
at the centrosome in mESCs so that it is not activated following induction of DSBs [70]. New
evidence suggests that H2AX phosphorylation in cultured ESCs is neither DNA–PKcs- nor
ATM-dependent but is in part ATR-dependent. This is associated with ssDNA gaps accumu‐
lation, reduced fork speed, and frequent fork reversal. All these features are lost upon onset
of differentiation [71]. Why is ATR spontaneously activated in mESCs? Ahuja et al. [71] show
that hypoxia, DNA methylation, and transcription do not seem to be the main cause of RS in
mESCs. RS appears to be linked to the maintenance of self-renewal of embryonic stem cells.
Turinetto et al. [68] demonstrated that γH2AX level decrease during mESCs differentiation,
while it increases upon treatment with self-renewal-enhancing small molecules such as GSK
and MEK inhibitor, which correlates with increased OCT4 and NANOG expression. Further,
a pluripotent state-specific gene, named FILIA, has been recently shown to be important for
genomic stability in mESCs [72]. This protein is constitutively localized to the centrosomes, is
recruited to DNA damage sites, where it stimulates PARP1 enzymatic activity, and contributes
to CHK2 activation independently of ATM.
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The main kind of spontaneous mutations observed in mESCs are loss of heterozygosity as a
consequence of chromosome loss/reduplication. However, the mutation rate of mESCs has
been found be to 100 times lower than that of isogenic somatic cells [73]. This is surprising
given the high level of RS observed in mESCs and may suggest that these cells could counter‐
balance genetic instability by increased DNA repair efficiency [74]. One of this could be
reduced efficiency of mitotic recombination in ESCs compared to somatic cells as observed
([73] and references therein). In addition, because mESCs have an inefficient G1/S checkpoint,
they activate DNA damage- and p53-dependent differentiation if injured, as a way to enter
apoptosis more easily since this checkpoint is restored in differentiated cells [75]. This latter
control mechanism then avoids that damaged cells would be part of the pool of differentiated
cells.
3.2. iPSCs
Somatic cells expressing defined pluripotency factors can be reprogrammed into iPSCs [76].
These cells share several similarities with ESCs such as a similar contracted cell cycle [77], the
ability to undergo self-renewal and differentiation, as well as expression of pluripotency
markers such as NANOG, OCT4, SOX2, and SSE-4 amongst others. Reprogramming increases
γH2AX levels [78–80] and induces accumulation of genomic aberrancies ranging from whole
chromosome aneuploidies, CNVs to point mutations [81], as well as epigenetic abnormalities
[82]. The mutation frequency of iPSCs is also increased and has been estimated to be 10 times
higher than that of ESCs [83–84]. This is in some way not surprising since the reprogramming
protocol involves overexpression of oncogenes, such as c-myc, that introduces RS. Decreased
genomic instability can be achieved by overexpression of the CHK1 kinase or by nucleosides
supplementation during reprogramming [80]. ATM is also important for reprogramming. It
has been reported that iPSCs deleted of ATM reprogram less efficiently and have increased
genomic instability. Interestingly, these cells display gene expression profiles similar to wild-
type ESCs and maintain the ability to differentiate into all three germ layers [85]. In line with
this data, iPSCs exhibit G2/M cell cycle arrest and efficient DSB repair if ATM-dependent
checkpoint activation signaling cascade is activated by ionizing radiation. iPSCs arrest the cell
cycle in G2-phase and repair DSB by HR probably by overexpressing DNA repair genes [86].
Altogether these observations point out to a general requirement for the DNA damage
checkpoint in sustaining reprogramming, suggesting that forced induction of proliferation
induces RS and cells need a functional DDR to cope with this.
3.3. ASCs
ASCs are characterized by a narrower differentiation potential than ESCs. These cells self-
renew to preserve both specific tissue and organ homeostasis throughout the life of an
individual. Although ASCs show much less signs of genomic instability than ESCs, they
deteriorate with age [87]. It is likely that the accumulation of lesions and mutations observed
during ageing of stem cells is caused by acquired defects in DNA repair pathways that reduce
stem cell potential. Interestingly, defective DNA repair is tightly linked to regeneration failure
in certain tissues. Fanconi anemia patients, who are deficient in ICL repair, are characterized
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by a premature failure of bone marrow hematopoiesis. This event is triggered by the accumu‐
lation of DNA lesions leading to excessive DDR activation in hematopoietic stem cells (HSCs)
and their progenitors [88]. In addition, NER is required for the maintenance of HSCs and
prevention of premature ageing [89]. NHEJ is critical for the maintenance of skeletal muscle
and muscle stem cells, since decreased Ku80 expression (a subunit of the heterodimeric
complex made of Ku70 and 80 proteins that that functions with DNA–PKcs in NHEJ) causes
accelerated exhaustion of stem cell pool and ageing [90]. In HSCs and their progenitors, ROS
accumulation can be provoked by loss of ATM, affecting cell cycle progression. Conditional
depletion of ATR or its downstream effector CHK1 is responsible for premature ageing
phenotypes in skin, bones, small intestine, and the hematopoietic system [91, 92], resulting in
apoptosis and cell cycle arrest because of rapid accumulation of DNA lesions [93, 94].
Interestingly, it has been reported that aging HSCs have a higher rate of genomic instability
than young HSCs, fuelled by a high level of RS generated by the reduced expression of
components of the MCM2-7 replicative helicase [95]. Reduced expression of the MCM3 gene
was also recently shown to be sufficient to impair hematopoietic progenitor cells due to RS
[94]. A recently identified protein, NUCLEOSTEMIN, rules a primary function in maintaining
the genomic stability of neural stem cells. This protein promotes recruitment of RAD51 to
replication-induced DNA damage foci and activates growth arrest independently of p53 [96].
Analysis of the transcriptional program of ESCs compared to ASCs (i.e., neural and hemato‐
poietic) showed unexpected high similarities of gene expression profiles and identified a core
set of about 200 genes expressed in all three cell types, accordingly coined as the “stemness”
factors [97].
Cell type Causes of genomic instability of stem cells
ESCs Short cell cycle
Inefficient checkpoints
RS
iPSCs
ASCs
Short cell cycle
Inefficient checkpoints
RS
Reprogramming-induced DNA damage
Mutations carry over
High mutation frequency
Aging-induced RS*
* Observed in HSCs [100].
Table 1. Summary of main causes of genomic instability of pluripotent stem cells.
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The cell cycle of ASCs is remarkably different from that of ESCs. ASCs are mostly quiescent
(being mostly in the G0 state) and display a very slow cell cycle. For example, about 75% of
HSCs reside in G0 [98], whereas ESCs grown in culture display less than 20% of cells in G1. It
has been suggested that HSCs may divide once every 145 days (about five times during a
mouse lifetime [99]), while ESCs divide every 11–12 h. These features make ASCs able to
activate checkpoints and allow efficient repair. Since NHEJ can also act during G0/G1 because
of its template independency, HSCs make an attempt to avoid DNA lesions by maintaining a
hypoxic status [100] and decreasing the generation of ROS. In these conditions, ATP is
generated mainly through glycolysis rather than mitochondrial respiration. Since this latter is
activated only following cell cycle entry [101, 102], it explains why the first process is mainly
employed by HSCs that are usually quiescent (Table 1).
4. Implications of PSCs genomic instability in regenerative medicine
PSCs are of great interest for their use in cell-based therapy. Current protocols involve PSCs
differentiation into a specific cell type and then injection into an organ in the aim of replacing
existing faulty cells. From a clinical point of view, this is a major concern due to the threat of
transplanting immature cells with instable genome. Indeed, when injected in mice, immature
PSCs induce teratoma. Hence, a greater understanding of the factors that regulate genomic
stability in PSCs is critical to address this issue.
4.1. Hurdles in translating iPSCs technology into the clinic: problems and perspectives
Genetic instability and a high mutation rate constitute the dark side of iPSCs when taken into
the clinic [4]. Hence, current efforts are made to generate iPSCs with reduced mutation load
and having more stable genomes. Ji et al. [103] have shown that antioxydants reduce the level
of γH2AX and de novo formation of CNVs in iPSCs suggesting that excessive ROS production
in iPSCs increases their genetic instability. Indeed, a very recent report that analyzed the
“metabolome” of naïve ESCs compared to that of primed ESCs show significant differences
between these two cell types, which in turn may impinge on the level of ROS [104]. Further,
recent work suggests that the use of non-integrative vectors to induce reprogramming
significantly reduces the number of CNVs in the resulting iPSCs [105, 106]. Furthermore, a
recent report that analyzed the mutational load of three distinct pluripotency induction
methods shows that a non-integrative approach results in lower mutation load than either
retrovirus or Sendai virus-based reprogramming methods [104]. Because integrative vectors
induce DNA damage by generating DSBs, this suggests that the manipulation of the DDR can
be a useful tool to reduce the genetic instability of iPSCs. It is then conceivable to think that
DNA damage generated during reprogramming may be not well taken care, one reason being
that iPSCs have inefficient checkpoints [86]. Indeed, a recent report indicates that manipulating
the DDR can decrease the genomic instability of iPSCs [80]. This work shows that increasing
the cellular levels of the CHK1 protein kinase decreases the level of γH2AX in these cells. In
sum, in order to reduce undesired genetic burden arising during reprogramming of somatic
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cells, supplementing medium with both antioxidants and nucleoside should be combined to
significantly reduce RS and CNVs in iPSCs.
In an effort to reduce genetic manipulation and consequent DNA damage, it has been shown
that several transcription factors needed for iPSCs generation (except OCT4) can be replaced
with a cocktail of chemical compounds [107]. More recently, generating iPSCs with a mix of
small molecules inhibitors that can also replace OCT4 appears to strongly suppress the level
of γH2AX, suggesting a reduction in spontaneous DNA damage, while keeping these cells
pluripotent [108, 109]. As an example for the downside of genetic manipulation, NANOG
expression has been shown to be cell cycle-regulated in human and mouse ESCs [53, 66, 110],
whereas during reprogramming, this transcription factor is under constitutive expression.
Altogether these data suggest that the use of an optimized set of chemical compounds may
not alter natural gene expression during reprogramming and therefore would likely reduce
unwanted off-target effects otherwise generated using genetic manipulation for reprogram‐
ming. Hence, chemical reprogramming remains a potentially more appropriate method since
standardization of the approach is foreseeable and paves a new way of keeping genomic
instability of iPSCs under control using pharmacological inhibitors.
Interestingly, mutation in the cell surface protein Glypican4 (Gpc4), implicated in the control
of the Wnt/ß-catenin signaling pathway, has been reported to strongly reduce formation of
teratoma upon implantation of mESCs in nude mice without affecting pluripotency [111]. Gpc4
mutant ESCs appear to be able to differentiate in all three embryonic layers when injected into
developing blastocysts, although with faster kinetics compared to wild-type ESCs. These data
propose Gpc4 as a promising target to modulate the teratogenic potential of ESCs. Indeed,
more recent data show that ESCs bearing a hypomorphic Gpc4 allele improve recovery of
motoneuron defects in a rat model for Parkinson disease without generating teratoma [112].
It is not yet known whether Gpc4 mutations have a similar effect also on human ESCs or iPSCs,
and whether spontaneous DNA damage and/or genomic instability are affected.
5. Conclusions and perspectives
Differentiation of iPSCs has been successfully achieved to generate hematopoietic cells,
neurons, pancreatic β-islet, and cardiomyocytes; however, production of other cell types is still
challenging. One major hurdle is the efficiency of differentiation that still remains very low.
In addition, PSCs show several signs of genetic instability, not only in culture but also in vivo
[71, 106], yet embryos manage to keep this instability under control by generating viable and
healthy organisms. Hence, the question arises of how this control is achieved. First, cells with
unstable genomes can be eliminated by apoptosis during differentiation, which is actually
what it is observed during in vitro differentiation. However, γH2AX detection in blastocysts
shows that most of the cells stain positive for this marker [71, 106], which makes unlikely that
most of them bear indeed highly unstable genomes. Another possibility is that the γH2AX
observed in these cells is not only a mark of genetic instability but perhaps also a marker of
other DNA transactions, including chromatin remodeling. Chromatin remodeling is known
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to change dramatically during differentiation; hence, the decrease of γH2AX observed upon
differentiation onset may be also due to changes in chromatin structure. If this is the case, the
chromatin structure and epigenetic marks responsible for constitutive γH2AX in ESCs remain
to be discovered. Furthermore, recent data show the presence of a high proportion of ssDNA
gaps in mESCs; however, the link between these gaps and the level of γH2AX is unclear.
Despite the high level of genetic instability, a highly contracted cell cycle and an inefficient
G1/S checkpoint, the mutation rate of mESCs has been surprisingly reported to be lower than
that of isogenic somatic cells. The significance of this discrepancy needs to be further under‐
stood.
How our current knowledge on PSCs can be translated into improving their genetic stability
so to foster the development of PSCs with lower mutation load that can be used with success
in regenerative medicine? In principle, identifying the molecular basis of genomic instability
of PSCs opens the perspective of manipulating the genes implicated, in the aim to decrease
their tendency to introduce mutations and so doing, reduce their teratogenicity. For instance,
being able to manipulate the structure of the cell cycle of PSCs so to decrease RS and still
maintain pluripotency may be of value. Further work in this direction is expected to generate
novel insights and hopes into this rather difficult though exciting task. Clinically-compatible
quantitative methods to comprehensively analyze the genetic stability of iPSCs would greatly
facilitate the selection process of most appropriate iPSCs clones. Recent efforts have shifted
the practice and proposed pathway signaling as readout to compare for functionality [113].
Ease of application and selection would guarantee large-scale testing in clinics.
Author details
Elena Lo Furno1, Siem van der Laan2 and Domenico Maiorano1*
*Address all correspondence to: domenico.maiorano@igh.cnrs.fr
1 Institute of Human Genetics, CNRS-UPR1142, Genome Surveillance and Stability
Laboratory, Department of Molecular Bases of Human Diseases, University of Montpellier,
Montpellier, France
2 CNRS FRE3690, Parc Euromedicine Cap Delta, Montpellier, France
References
[1] Wood RD (1996) DNA repair in eukaryotes. Annual Review of Biochemistry 65: 135–
167.
[2] Kenyon J, Gerson SL (2007) The role of DNA damage repair in aging of adult stem cells.
Nucleic Acids Research 35: 7557–7565.
Genomic Instability of Pluripotent Stem Cells: Origin and Consequences
http://dx.doi.org/10.5772/62906
129
[3] Hakem R (2008) DNA-damage repair; the good, the bad, and the ugly. The EMBO
Journal 27: 589–605.
[4] Pera MF (2011) Stem cells: The dark side of induced pluripotency. Nature 471: 46–47.
[5] Shen Z (2011) Genomic instability and cancer: an introduction. Journal of Molecular
Cell Biology 3: 1–3.
[6] Hartwell L (1992) Defects in a cell cycle checkpoint may be responsible for the genomic
instability of cancer cells. Cell 71: 543–546.
[7] Matt S, Hofmann TG (2016) The DNA damage-induced cell death response: a roadmap
to kill cancer cells. Cellular and molecular life sciences: CMLS.
[8] Goldstein M, Kastan MB (2015) The DNA damage response: implications for tumor
responses to radiation and chemotherapy. Annual Review of Medicine 66: 129–143.
[9] Schuyler SC, Wu YF, Kuan VJ (2012) The Mad1-Mad2 balancing act—a damaged
spindle checkpoint in chromosome instability and cancer. Journal of Cell Science 125:
4197–4206.
[10] Waters CA, Strande NT, Pryor JM, Strom CN, Mieczkowski P, et al. (2014) The fidelity
of the ligation step determines how ends are resolved during nonhomologous end
joining. Nature Communications 5: 4286.
[11] Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, et al. (1995) A single ataxia telan‐
giectasia gene with a product similar to PI-3 kinase. Science 268: 1749–1753.
[12] Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER, 3rd, Hurov KE, et al. (2007)
ATM and ATR substrate analysis reveals extensive protein networks responsive to
DNA damage. Science 316: 1160–1166.
[13] Gonzalez Besteiro MA, Gottifredi V (2015) The fork and the kinase: a DNA replication
tale from a CHK1 perspective. Mutation Research Reviews in Mutation Research 763:
168–180.
[14] Cimprich KA, Cortez D (2008) ATR: an essential regulator of genome integrity. Nature
Reviews Molecular Cell Biology 9: 616–627.
[15] Vidal-Eychenie S, Decaillet C, Basbous J, Constantinou A (2013) DNA structure-specific
priming of ATR activation by DNA–PKcs. The Journal of Cell Biology 202: 421–429.
[16] Lin YF, Shih HY, Shang Z, Matsunaga S, Chen BP (2014) DNA–PKcs is required to
maintain stability of Chk1 and Claspin for optimal replication stress response. Nucleic
Acids Research 42: 4463–4473.
[17] Ashley AK, Shrivastav M, Nie J, Amerin C, Troksa K, et al. (2014) DNA–PK phosphor‐
ylation of RPA32 Ser4/Ser8 regulates replication stress checkpoint activation, fork
restart, homologous recombination and mitotic catastrophe. DNA Repair 21: 131–139.
Pluripotent Stem Cells - From the Bench to the Clinic130
[18] Hekmat-Nejad M, You Z, Yee MC, Newport JW, Cimprich KA (2000) Xenopus ATR is
a replication-dependent chromatin-binding protein required for the DNA replication
checkpoint. Current Biology 10: 1565–1573.
[19] Byun TS, Pacek M, Yee MC, Walter JC, Cimprich KA (2005) Functional uncoupling of
MCM helicase and DNA polymerase activities activates the ATR-dependent check‐
point. Genes & Development 19: 1040–1052.
[20] Van C, Yan S, Michael WM, Waga S, Cimprich KA (2010) Continued primer synthesis
at stalled replication forks contributes to checkpoint activation. The Journal of Cell
Biology 189: 233–246.
[21] Recolin B, Van der Laan S, Maiorano D (2012) Role of replication protein A as sensor
in activation of the S-phase checkpoint in Xenopus egg extracts. Nucleic Acids Research
40: 3431–3442.
[22] Betous R, Pillaire MJ, Pierini L, van der Laan S, Recolin B, et al. (2013) DNA polymerase
kappa-dependent DNA synthesis at stalled replication forks is important for CHK1
activation. The EMBO Journal 32: 2172–2185.
[23] Duursma AM, Driscoll R, Elias JE, Cimprich KA (2013) A role for the MRN complex in
ATR activation via TOPBP1 recruitment. Molecular Cell 50: 116–122.
[24] Lee J, Dunphy WG (2013) The Mre11-Rad50-Nbs1 (MRN) complex has a specific role
in the activation of Chk1 in response to stalled replication forks. Molecular Biology of
the Cell 24: 1343–1353.
[25] Ward IM, Chen J (2001) Histone H2AX is phosphorylated in an ATR-dependent manner
in response to replicational stress. Journal of Biological Chemistry 276: 47759–47762.
[26] Bakkenist CJ, Kastan MB (2003) DNA damage activates ATM through intermolecular
autophosphorylation and dimer dissociation. Nature 421: 499–506.
[27] Lukas J, Lukas C, Bartek J (2011) More than just a focus: The chromatin response to
DNA damage and its role in genome integrity maintenance. Nature Cell Biology 13:
1161–1169.
[28] Lambert S, Carr AM (2013) Impediments to replication fork movement: stabilisation,
reactivation and genome instability. Chromosoma 122: 33–45.
[29] Zeman MK, Cimprich KA (2014) Causes and consequences of replication stress. Nature
Cell Biology 16: 2–9.
[30] Fraga CG, Shigenaga MK, Park JW, Degan P, Ames BN (1990) Oxidative damage to
DNA during aging: 8-hydroxy-2′-deoxyguanosine in rat organ DNA and urine.
Proceedings of the National Academy of Sciences of the United States of America 87:
4533–4537.
Genomic Instability of Pluripotent Stem Cells: Origin and Consequences
http://dx.doi.org/10.5772/62906
131
[31] Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, et al. (2005)
Activation of the DNA damage checkpoint and genomic instability in human precan‐
cerous lesions. Nature 434: 907–913.
[32] Neelsen KJ, Zanini IM, Mijic S, Herrador R, Zellweger R, et al. (2013) Deregulated origin
licensing leads to chromosomal breaks by rereplication of a gapped DNA template.
Genes & Development 27: 2537–2542.
[33] Jones RM, Mortusewicz O, Afzal I, Lorvellec M, Garcia P, et al. (2012) Increased
replication initiation and conflicts with transcription underlie Cyclin E-induced
replication stress. Oncogene.
[34] Recolin B, van der Laan S, Tsanov N, Maiorano D (2014) Molecular mechanisms of
DNA replication checkpoint activation. Genes 5: 147–175.
[35] Neelsen KJ, Zanini IM, Herrador R, Lopes M (2013) Oncogenes induce genotoxic stress
by mitotic processing of unusual replication intermediates. The Journal of Cell Biology
200: 699–708.
[36] Lukas C, Savic V, Bekker-Jensen S, Doil C, Neumann B, et al. (2011) 53BP1 nuclear
bodies form around DNA lesions generated by mitotic transmission of chromosomes
under replication stress. Nature Cell Biology 13: 243–253.
[37] Loeb LA (1991) Mutator phenotype may be required for multistage carcinogenesis.
Cancer Research 51: 3075–3079.
[38] Halazonetis TD, Gorgoulis VG, Bartek J (2008) An oncogene-induced DNA damage
model for cancer development. Science 319: 1352–1355.
[39] Kinzler KW, Vogelstein B (1997) Cancer-susceptibility genes. Gatekeepers and care‐
takers. Nature 386: 761, 763.
[40] Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, et al. (1993) The human
mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon
cancer. Cell 75: 1027–1038.
[41] Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, et al. (1993) Mutations of a mutS
homolog in hereditary nonpolyposis colorectal cancer. Cell 75: 1215–1225.
[42] Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, et al. (2002) Inherited
variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors.
Nature Genetics 30: 227–232.
[43] Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194: 23–28.
[44] Longo L, Bygrave A, Grosveld FG, Pandolfi PP (1997) The chromosome make-up of
mouse embryonic stem cells is predictive of somatic and germ cell chimaerism.
Transgenic Research 6: 321–328.
Pluripotent Stem Cells - From the Bench to the Clinic132
[45] Liu X, Wu H, Loring J, Hormuzdi S, Disteche CM, et al. (1997) Trisomy eight in ES cells
is a common potential problem in gene targeting and interferes with germ line
transmission. Developmental Dynamics 209: 85–91.
[46] Maitra A, Arking DE, Shivapurkar N, Ikeda M, Stastny V, et al. (2005) Genomic
alterations in cultured human embryonic stem cells. Nature Genetics 37: 1099–1103.
[47] Lefort N, Feyeux M, Bas C, Feraud O, Bennaceur-Griscelli A, et al. (2008) Human
embryonic stem cells reveal recurrent genomic instability at 20q11.21. Nature Biotech‐
nology 26: 1364–1366.
[48] Baker DE, Harrison NJ, Maltby E, Smith K, Moore HD, et al. (2007) Adaptation to
culture of human embryonic stem cells and oncogenesis in vivo. Nature Biotechnology
25: 207–215.
[49] Lamm N, Ben-David U, Golan-Lev T, Storchova Z, Benvenisty N, et al. (2016) Genomic
instability in human pluripotent stem cells arises from replicative stress and chromo‐
some condensation defects. Cell Stem Cell 18: 253–261.
[50] Becker KA, Ghule PN, Therrien JA, Lian JB, Stein JL, et al. (2006) Self-renewal of human
embryonic stem cells is supported by a shortened G1 cell cycle phase. Journal of Cellular
Physiology 209: 883–893.
[51] Savatier P, Lapillonne H, Jirmanova L, Vitelli L, Samarut J (2002) Analysis of the cell
cycle in mouse embryonic stem cells. Methods in Molecular Biology 185: 27–33.
[52] Ballabeni A, Park IH, Zhao R, Wang W, Lerou PH, et al. (2011) Cell cycle adaptations
of embryonic stem cells. Proceedings of the National Academy of Sciences of the United
States of America 108: 19252–19257.
[53] van der Laan S, Tsanov N, Crozet C, Maiorano D (2013) High Dub3 expression in mouse
ESCs couples the G1/S checkpoint to pluripotency. Molecular Cell 52: 366–379.
[54] Meshorer E, Misteli T (2006) Chromatin in pluripotent embryonic stem cells and
differentiation. Nature Reviews Molecular Cell biology 7: 540–546.
[55] Pajerowski JD, Dahl KN, Zhong FL, Sammak PJ, Discher DE (2007) Physical plasticity
of the nucleus in stem cell differentiation. Proceedings of the National Academy of
Sciences of the United States of America 104: 15619–15624.
[56] Prost S, Bellamy CO, Clarke AR, Wyllie AH, Harrison DJ (1998) p53-independent DNA
repair and cell cycle arrest in embryonic stem cells. FEBS Letters 425: 499–504.
[57] Aladjem MI, Spike BT, Rodewald LW, Hope TJ, Klemm M, et al. (1998) ES cells do not
activate p53-dependent stress responses and undergo p53-independent apoptosis in
response to DNA damage. Current Biology 8: 145–155.
[58] Koledova Z, Kafkova LR, Kramer A, Divoky V (2010) DNA damage-induced degra‐
dation of Cdc25A does not lead to inhibition of Cdk2 activity in mouse embryonic stem
cells. Stem Cells 28: 450–461.
Genomic Instability of Pluripotent Stem Cells: Origin and Consequences
http://dx.doi.org/10.5772/62906
133
[59] Barta T, Vinarsky V, Holubcova Z, Dolezalova D, Verner J, et al. (2010) Human
embryonic stem cells are capable of executing G1/S checkpoint activation. Stem Cells
28: 1143–1152.
[60] Desmarais JA, Hoffmann MJ, Bingham G, Gagou ME, Meuth M, et al. (2012) Human
embryonic stem cells fail to activate CHK1 and commit to apoptosis in response to DNA
replication stress. Stem Cells 30: 1385–1393.
[61] Sabapathy K, Klemm M, Jaenisch R, Wagner EF (1997) Regulation of ES cell differen‐
tiation by functional and conformational modulation of p53. EMBO Journal 16: 6217–
6229.
[62] Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J (2001) The ATM-Chk2-Cdc25A
checkpoint pathway guards against radioresistant DNA synthesis. Nature 410: 842–
847.
[63] Delgado-Diaz MR, Martin Y, Berg A, Freire R, Smits VA (2014) Dub3 controls DNA
damage signalling by direct deubiquitination of H2AX. Molecular oncology 8: 884–893.
[64] Momcilovic O, Navara C, Schatten G (2011) Cell cycle adaptations and maintenance of
genomic integrity in embryonic stem cells and induced pluripotent stem cells. Results
and Problems in Cell Differentiation 53: 415–458.
[65] Banuelos CA, Banath JP, MacPhail SH, Zhao J, Eaves CA, et al. (2008) Mouse but not
human embryonic stem cells are deficient in rejoining of ionizing radiation-induced
DNA double-strand breaks. DNA Repair 7: 1471–1483.
[66] Zhang X, Neganova I, Przyborski S, Yang C, Cooke M, et al. (2009) A role for NANOG
in G1 to S transition in human embryonic stem cells through direct binding of CDK6
and CDC25A. Journal of Cell Biology 184: 67–82.
[67] Pauklin S, Vallier L (2013) The cell-cycle state of stem cells determines cell fate pro‐
pensity. Cell 155: 135–147.
[68] Turinetto V, Orlando L, Sanchez-Ripoll Y, Kumpfmueller B, Storm MP, et al. (2012)
High basal gammaH2AX levels sustain self-renewal of mouse embryonic and induced
pluripotent stem cells. Stem Cells 30: 1414–1423.
[69] Banath JP, Banuelos CA, Klokov D, MacPhail SM, Lansdorp PM, et al. (2009) Explan‐
ation for excessive DNA single-strand breaks and endogenous repair foci in pluripotent
mouse embryonic stem cells. Experimental Cell Research 315: 1505–1520.
[70] Hong Y, Stambrook PJ (2004) Restoration of an absent G1 arrest and protection from
apoptosis in embryonic stem cells after ionizing radiation. Proceedings of the National
Academy of Sciences of the United States of America 101: 14443–14448.
[71] Ahuja AK, Jodkowska K, Teloni F, Bizard AH, Zellweger R, et al. (2016) A short G1
phase imposes constitutive replication stress and fork remodelling in mouse embryonic
stem cells. Nature Communications 7: 10660.
Pluripotent Stem Cells - From the Bench to the Clinic134
[72] Zhao B, Zhang WD, Duan YL, Lu YQ, Cun YX, et al. (2015) Filia is an ESC-specific
regulator of DNA damage response and safeguards genomic stability. Cell Stem Cell
16: 684–698.
[73] Hong Y, Cervantes RB, Tichy E, Tischfield JA, Stambrook PJ (2007) Protecting genomic
integrity in somatic cells and embryonic stem cells. Mutation Research 614: 48–55.
[74] Maynard S, Swistowska AM, Lee JW, Liu Y, Liu ST, et al. (2008) Human embryonic
stem cells have enhanced repair of multiple forms of DNA damage. Stem Cells 26: 2266–
2274.
[75] Lin T, Chao C, Saito S, Mazur SJ, Murphy ME, et al. (2005) p53 induces differentiation
of mouse embryonic stem cells by suppressing Nanog expression. Nature Cell Biology
7: 165–171.
[76] Yamanaka S (2008) Induction of pluripotent stem cells from mouse fibroblasts by four
transcription factors. Cell Proliferation 41(Suppl 1): 51–56.
[77] Ruiz S, Panopoulos AD, Herrerias A, Bissig KD, Lutz M, et al. (2011) A high prolifer‐
ation rate is required for cell reprogramming and maintenance of human embryonic
stem cell identity. Current Biology: CB 21: 45–52.
[78] Blasco MA, Serrano M, Fernandez-Capetillo O (2011) Genomic instability in iPS: time
for a break. The EMBO Journal 30: 991–993.
[79] Marion RM, Strati K, Li H, Murga M, Blanco R, et al. (2009) A p53-mediated DNA
damage response limits reprogramming to ensure iPS cell genomic integrity. Nature
460: 1149–1153.
[80] Ruiz S, Lopez-Contreras AJ, Gabut M, Marion RM, Gutierrez-Martinez P, et al. (2015)
Limiting replication stress during somatic cell reprogramming reduces genomic
instability in induced pluripotent stem cells. Nature Communications 6: 8036.
[81] Weissbein U, Benvenisty N, Ben-David U (2014) Quality control: Genome maintenance
in pluripotent stem cells. The Journal of Cell Biology 204: 153–163.
[82] Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, et al. (2011) Hotspots of aberrant
epigenomic reprogramming in human induced pluripotent stem cells. Nature 471: 68–
73.
[83] Ji J, Ng SH, Sharma V, Neculai D, Hussein S, et al. (2012) Elevated coding mutation rate
during the reprogramming of human somatic cells into induced pluripotent stem cells.
Stem Cells 30: 435–440.
[84] Gore A, Li Z, Fung HL, Young JE, Agarwal S, et al. (2011) Somatic coding mutations in
human induced pluripotent stem cells. Nature 471: 63–67.
[85] Kinoshita T, Nagamatsu G, Kosaka T, Takubo K, Hotta A, et al. (2011) Ataxia-telan‐
giectasia mutated (ATM) deficiency decreases reprogramming efficiency and leads to
Genomic Instability of Pluripotent Stem Cells: Origin and Consequences
http://dx.doi.org/10.5772/62906
135
genomic instability in iPS cells. Biochemical and Biophysical Research Communica‐
tions 407: 321–326.
[86] Momcilovic O, Knobloch L, Fornsaglio J, Varum S, Easley C, et al. (2010) DNA damage
responses in human induced pluripotent stem cells and embryonic stem cells. PLos
One 5: e13410.
[87] Liu L, Rando TA (2011) Manifestations and mechanisms of stem cell aging. Journal Cell
Biology 193: 257–266.
[88] Ceccaldi R, Parmar K, Mouly E, Delord M, Kim JM, et al. (2012) Bone marrow failure
in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that
impairs hematopoietic stem and progenitor cells. Cell Stem Cell 11: 36–49.
[89] Rossi DJ, Bryder D, Seita J, Nussenzweig A, Hoeijmakers J, et al. (2007) Deficiencies in
DNA damage repair limit the function of haematopoietic stem cells with age. Nature
447: 725–729.
[90] Didier N, Hourde C, Amthor H, Marazzi G, Sassoon D (2012) Loss of a single allele for
Ku80 leads to progenitor dysfunction and accelerated aging in skeletal muscle. EMBO
Molecular Medicine 4: 910–923.
[91] Ruzankina Y, Pinzon-Guzman C, Asare A, Ong T, Pontano L, et al. (2007) Deletion of
the developmentally essential gene ATR in adult mice leads to age-related phenotypes
and stem cell loss. Cell Stem Cell 1: 113–126.
[92] Greenow KR, Clarke AR, Jones RH (2009) Chk1 deficiency in the mouse small intestine
results in p53-independent crypt death and subsequent intestinal compensation.
Oncogene 28: 1443–1453.
[93] Ruzankina Y, Schoppy DW, Asare A, Clark CE, Vonderheide RH, et al. (2009) Tissue
regenerative delays and synthetic lethality in adult mice after combined deletion of Atr
and Trp53. Nature Genetics 41: 1144–1149.
[94] Alvarez S, Diaz M, Flach J, Rodriguez-Acebes S, Lopez-Contreras AJ, et al. (2015)
Replication stress caused by low MCM expression limits fetal erythropoiesis and
hematopoietic stem cell functionality. Nature Communications 6: 8548.
[95] Flach J, Bakker ST, Mohrin M, Conroy PC, Pietras EM, et al. (2014) Replication stress is
a potent driver of functional decline in ageing haematopoietic stem cells. Nature 512:
198–202.
[96] Meng L, Lin T, Peng G, Hsu JK, Lee S, et al. (2013) Nucleostemin deletion reveals an
essential mechanism that maintains the genomic stability of stem and progenitor cells.
Proceedings of the National Academy of Sciences of the United States of America 110:
11415–11420.
[97] Ramalho-Santos M, Yoon S, Matsuzaki Y, Mulligan RC, Melton DA (2002) “Stemness”:
transcriptional profiling of embryonic and adult stem cells. Science 298: 597–600.
Pluripotent Stem Cells - From the Bench to the Clinic136
[98] Cheshier SH, Morrison SJ, Liao X, Weissman IL (1999) In vivo proliferation and cell
cycle kinetics of long-term self-renewing hematopoietic stem cells. Proceedings of the
National Academy of Sciences of the United States of America 96: 3120–3125.
[99] Wilson A, Laurenti E, Oser G, van der Wath RC, Blanco-Bose W, et al. (2008) Hemato‐
poietic stem cells reversibly switch from dormancy to self-renewal during homeostasis
and repair. Cell 135: 1118–1129.
[100] Nombela-Arrieta C, Pivarnik G, Winkel B, Canty KJ, Harley B, et al. (2013) Quantitative
imaging of haematopoietic stem and progenitor cell localization and hypoxic status in
the bone marrow microenvironment. Nature Cell Biology 15: 533–543.
[101] Takubo K, Nagamatsu G, Kobayashi CI, Nakamura-Ishizu A, Kobayashi H, et al. (2013)
Regulation of glycolysis by Pdk functions as a metabolic checkpoint for cell cycle
quiescence in hematopoietic stem cells. Cell Stem Cell 12: 49–61.
[102] Yu WM, Liu X, Shen J, Jovanovic O, Pohl EE, et al. (2013) Metabolic regulation by the
mitochondrial phosphatase PTPMT1 is required for hematopoietic stem cell differen‐
tiation. Cell Stem Cell 12: 62–74.
[103] Ji J, Sharma V, Qi S, Guarch ME, Zhao P, et al. (2014) Antioxidant supplementation
reduces genomic aberrations in human induced pluripotent stem cells. Stem Cell
Reports 2: 44–51.
[104] Sperber H, Mathieu J, Wang Y, Ferreccio A, Hesson J, et al. (2015) The metabolome
regulates the epigenetic landscape during naive-to-primed human embryonic stem cell
transition. Nature Cell Biology 17: 1523–1535.
[105] Kang X, Yu Q, Huang Y, Song B, Chen Y, et al. (2015) Effects of integrating and non-
integrating reprogramming methods on copy number variation and genomic stability
of human induced pluripotent stem cells. PLos One 10: e0131128.
[106] Sobol M, Raykova D, Cavelier L, Khalfallah A, Schuster J, et al. (2015) Methods of
reprogramming to induced pluripotent stem cell associated with chromosomal
integrity and delineation of a chromosome 5q candidate region for growth advantage.
Stem Cells and Development 24: 2032–2040.
[107] Zhu S, Li W, Zhou H, Wei W, Ambasudhan R, et al. (2010) Reprogramming of human
primary somatic cells by OCT4 and chemical compounds. Cell Stem Cell 7: 651–655.
[108] Xu Y, Shi Y, Ding S (2008) A chemical approach to stem-cell biology and regenerative
medicine. Nature 453: 338–344.
[109] Park HS, Hwang I, Choi KA, Jeong H, Lee JY, et al. (2015) Generation of induced
pluripotent stem cells without genetic defects by small molecules. Biomaterials 39: 47–
58.
Genomic Instability of Pluripotent Stem Cells: Origin and Consequences
http://dx.doi.org/10.5772/62906
137
[110] Singh AM, Chappell J, Trost R, Lin L, Wang T, et al. (2013) Cell-cycle control of
developmentally regulated transcription factors accounts for heterogeneity in human
pluripotent cells. Stem Cell Reports 1: 532–544.
[111] Fico A, De Chevigny A, Egea J, Bosl MR, Cremer H, et al. (2012) Modulating Glypican4
suppresses tumorigenicity of embryonic stem cells while preserving self-renewal and
pluripotency. Stem Cells 30: 1863–1874.
[112] Fico A, de Chevigny A, Melon C, Bohic M, Kerkerian-Le Goff L, et al. (2014) Reducing
glypican-4 in ES cells improves recovery in a rat model of Parkinson’s disease by
increasing the production of dopaminergic neurons and decreasing teratoma forma‐
tion. The Journal of Neuroscience 34: 8318–8323.
[113] Makarev E, Fortney K, Litovchenko M, Braunewell KH, Zhavoronkov A, et al. (2015)
Quantifying signaling pathway activation to monitor the quality of induced pluripo‐
tent stem cells. Oncotarget 6: 23204–23212.
Pluripotent Stem Cells - From the Bench to the Clinic138
